Literature DB >> 1701659

Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours.

J M Cline1, D E Thrall, R L Page, A J Franko, J A Raleigh.   

Abstract

An immunoperoxidase technique has been used to detect the in vivo binding of a 2-nitroimidazole hypoxia marker in histochemical sections of a variety of excised canine tumours. The binding occurred 10-12 cell diameters away from tumour blood vessels, consistent with the expected location of hypoxic cells in tissues in which oxygen concentration gradients are established by diffusion. Hypoxic fractions ranging from 4 to 13% have been estimated on the basis of morphometric analysis of multiple tumour sections. The binding of the marker was restricted to the cytoplasm of the cells. The marker appeared in regions adjacent to necrosis but also in regions free of necrosis. As in earlier autoradiography studies, binding was occasionally observed in cells adjacent to tumour blood vessels. Generally, binding to normal tissues was not observed. However, binding to smooth muscle cells surrounding arterioles in some sections of normal tissue and tumour tissue was observed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701659      PMCID: PMC1971560          DOI: 10.1038/bjc.1990.411

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

1.  Regioselective formation of a misonidazole-glutathione conjugate as a function of pH during chemical reduction.

Authors:  E Chacon; C J Morrow; A A Leon; J L Born; B R Smith
Journal:  Biochem Pharmacol       Date:  1988-01-15       Impact factor: 5.858

2.  The endothelium--modulator of vascular smooth-muscle tone.

Authors:  P M Vanhoutte
Journal:  N Engl J Med       Date:  1988-08-25       Impact factor: 91.245

3.  Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo.

Authors:  R J Maxwell; P Workman; J R Griffiths
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-04       Impact factor: 7.038

4.  Is misonidazole binding to mouse tissues a measure of cellular pO2?

Authors:  D J Van Os-Corby; C J Koch; J D Chapman
Journal:  Biochem Pharmacol       Date:  1987-10-15       Impact factor: 5.858

Review 5.  Hypoxic cells as specific drug targets for chemotherapy.

Authors:  K A Kennedy
Journal:  Anticancer Drug Des       Date:  1987-10

6.  Intercapillary distance measurement as an indicator of hypoxia in carcinoma of the cervix uteri.

Authors:  H K Awwad; M el Naggar; N Mocktar; M Barsoum
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-08       Impact factor: 7.038

7.  Binding of misonidazole to hypoxic cells in monolayer and spheroid culture: evidence that a side-chain label is bound as efficiently as a ring label.

Authors:  J A Raleigh; A J Franko; C J Koch; J L Born
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

8.  Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours.

Authors:  J A Raleigh; G G Miller; A J Franko; C J Koch; A F Fuciarelli; D A Kelly
Journal:  Br J Cancer       Date:  1987-10       Impact factor: 7.640

9.  The histological structure of some human lung cancers and the possible implications for radiotherapy.

Authors:  R H THOMLINSON; L H GRAY
Journal:  Br J Cancer       Date:  1955-12       Impact factor: 7.640

10.  A novel technique for measuring human tissue pO2 at the cellular level.

Authors:  R C Urtasun; C J Koch; A J Franko; J A Raleigh; J D Chapman
Journal:  Br J Cancer       Date:  1986-09       Impact factor: 7.640

View more
  10 in total

1.  Lung dysfunction causes systemic hypoxia in estrogen receptor beta knockout (ERbeta-/-) mice.

Authors:  Andrea Morani; Rodrigo P A Barros; Otabek Imamov; Kjell Hultenby; Anders Arner; Margaret Warner; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-24       Impact factor: 11.205

2.  Early wound healing exhibits cytokine surge without evidence of hypoxia.

Authors:  Z A Haroon; J A Raleigh; C S Greenberg; M W Dewhirst
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

3.  Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas.

Authors:  H W M van Laarhoven; G Gambarota; A Heerschap; J Lok; I Verhagen; A Corti; S Toma; C Gallo Stampino; A van der Kogel; C J A Punt
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.850

4.  Marking hypoxic cells for complement and cytotoxic T lymphocyte-mediated lysis: using pimonidazole.

Authors:  S C Chou; P M Flood; J A Raleigh
Journal:  Br J Cancer Suppl       Date:  1996-07

5.  ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.

Authors:  James Greenaway; Jack Henkin; Jack Lawler; Roger Moorehead; Jim Petrik
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

6.  Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats.

Authors:  Daniel P Bradley; Jean J Tessier; Susan E Ashton; John C Waterton; Zena Wilson; Philip L Worthington; Anderson J Ryan
Journal:  Neoplasia       Date:  2007-05       Impact factor: 5.715

7.  Quantification of longitudinal tissue pO2 gradients in window chamber tumours: impact on tumour hypoxia.

Authors:  M W Dewhirst; E T Ong; R D Braun; B Smith; B Klitzman; S M Evans; D Wilson
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

Review 8.  Canine Cancer: Strategies in Experimental Therapeutics.

Authors:  Douglas H Thamm
Journal:  Front Oncol       Date:  2019-11-15       Impact factor: 6.244

9.  An enzyme-linked immunosorbent assay for hypoxia marker binding in tumours.

Authors:  J A Raleigh; J K La Dine; J M Cline; D E Thrall
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

10.  Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver.

Authors:  G E Arteel; R G Thurman; J M Yates; J A Raleigh
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.